Did Biden Bet the Future of America on the "Lithium Triangle"?
FREE investor's report details the plan to cut more ties with China and how it could create the next boom for early investors. But you must act fast.
Discover the one company set to break China's grip

LUCD Insider Trading

Insider Ownership Percentage: 5.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $57,568.80

Lucid Diagnostics Insider Trading History Chart

This chart shows the insider buying and selling history at Lucid Diagnostics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lucid Diagnostics Share Price & Price History

Current Price: $1.71
Price Change: Price Decrease of -0.02 (-1.16%)
As of 10/5/2022 01:00 AM ET

This chart shows the closing price history over time for LUCD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Lucid Diagnostics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/20/2022Stanley LapidusDirectorSell33,864$1.70$57,568.80135,456View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Lucid Diagnostics (NASDAQ:LUCD)

6.48% of Lucid Diagnostics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LUCD by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Lucid Diagnostics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/30/2022Verition Fund Management LLC46,709$0.11M0.0%+29.2%0.123%Search for SEC Filing on Google Icon
8/15/2022Nantahala Capital Management LLC308,978$0.70M0.0%-2.0%0.815%Search for SEC Filing on Google Icon
8/15/2022Luminus Management LLC873,804$1.98M0.6%+15.7%2.304%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC24,265$55K0.0%N/A0.064%Search for SEC Filing on Google Icon
8/12/2022LPL Financial LLC14,400$33K0.0%N/A0.038%Search for SEC Filing on Google Icon
8/11/2022Bank of Montreal Can15,524$35K0.0%N/A0.041%Search for SEC Filing on Google Icon
7/22/2022Geneos Wealth Management Inc.42,450$98K0.0%-32.0%0.112%Search for SEC Filing on Google Icon
6/2/2022Verition Fund Management LLC36,166$0.12M0.0%N/A0.095%Search for SEC Filing on Google Icon
5/23/2022Cantor Fitzgerald L. P.333,717$1.12M0.1%-20.0%0.880%Search for SEC Filing on Google Icon
5/17/2022Geneos Wealth Management Inc.62,450$0.21M0.0%N/A0.165%Search for SEC Filing on Google Icon
5/16/2022State Street Corp56,693$0.19M0.0%+24.4%0.149%Search for SEC Filing on Google Icon
5/13/2022Verition Fund Management LLC36,166$0.12M0.0%N/A0.095%Search for SEC Filing on Google Icon
5/13/2022Nantahala Capital Management LLC315,414$1.06M0.0%-27.5%0.832%Search for SEC Filing on Google Icon
5/13/2022Luminus Management LLC755,482$2.54M0.6%-39.9%1.992%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.312,876$1.05M0.0%+25.6%0.825%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.67,565$0.23M0.0%+18.7%0.178%Search for SEC Filing on Google Icon
2/15/2022KCL Capital L.P.10,000$54K0.0%N/A0.027%Search for SEC Filing on Google Icon
2/15/2022Covalis Capital LLP134,532$0.72M0.3%N/A0.365%Search for SEC Filing on Google Icon
2/2/2022New York State Common Retirement Fund13,800$74K0.0%N/A0.037%Search for SEC Filing on Google Icon
2/1/2022Kornitzer Capital Management Inc. KS133,000$0.71M0.0%N/A0.361%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Lucid Diagnostics logo
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Read More on Lucid Diagnostics

Today's Range

Now: $1.71
Low: $1.66
High: $1.75

50 Day Range

MA: $2.40
Low: $1.53
High: $3.45

52 Week Range

Now: $1.71
Low: $1.51
High: $13.52

Volume

33,242 shs

Average Volume

138,760 shs

Market Capitalization

$64.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Lucid Diagnostics?

Lucid Diagnostics' top insider shareholders include:
  1. Stanley Lapidus (Director)
Learn More about top insider investors at Lucid Diagnostics.